Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

How Long Should Methotrexate Be Held Following Seasonal Vaccinations?

Arthritis & Rheumatology  |  February 1, 2023

Vaccinations against preventable diseases, including seasonal influenza, are strongly recommended for patients with rheumatoid arthritis (RA), who are at increased risk of infections as a result of underlying immune dysfunction and treatment-induced immunosuppression. Park et al. conducted this clinical trial to investigate whether discontinuing methotrexate for one week after seasonal influenza vaccination is noninferior to discontinuing it for two weeks after vaccination in patients with RA.

First Biosimilar to Adalimumab (Humira) Enters the U.S. Market After Years of Legal Battles

Michele B. Kaufman, PharmD, BCGP  |  January 31, 2023

After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.

Rheumatology Online: Disseminating the State of the Art on Social Media at ACR Convergence 2022

Mithu Maheswaranathan  |  January 30, 2023

PHILADELPHIA—A session on social media in rheumatology at ACR Convergence 2022 focused on how to use social media to promote one’s work and collaborate on international research projects, as well as the use of podcasts in educating rheumatologists. Engaging with Social Media at Conferences Jean Liew, MD, MS, assistant professor of medicine in the Section…

Key Facts on Billing Drug Wastage

From the College  |  January 24, 2023

The ACR has compiled guidelines and tips on how to use the JW modifier and correctly bill Medicare for discarded drugs and biologicals. This modifier can be applied only to unused amounts from a single-dose vial or package.

CMS Announces Timeline for Drug Negotiations

From the College  |  January 20, 2023

This month, the CMS will begin steps to develop a drug pricing negotiation process as allowed by the Inflation Reduction Act. The ACR plans to participate in public comment opportunities.

Rheumatology Association of Iowa Supports Members & Advocates for Patients

Linda Childers  |  January 20, 2023

One of the newer state rheumatology organizations, the Rheumatology Association of Iowa, brings together rheumatology professionals, offering connections to fill rural care needs and advocate for policies that support patient care. The organization’s 9th annual meeting will be Feb. 24–25.

A World of Difference: Updates from the Global Rheumatology Summit

Jason Liebowitz, MD, FACR  |  January 20, 2023

The second annual Global Rheumatology Summit focused on climate change, conflict and migration, as well as other global issues in rheumatology.

Dr. Michelle Petri: A Guiding Light for Patients with Lupus

Jason Liebowitz, MD, FACR  |  January 17, 2023

Systemic lupus erythematosus (SLE) affects a substantial number of patients worldwide, with an estimated prevalence in North America of 241 per 100,000 people.1 The morbidity and mortality associated with the condition can be significant, and thus research on this disease continues to be of utmost importance. The story of one of the world’s leading experts…

ACR Image Competition 2022 Results, Part 2

Jonathan T. Cheah, MBBS  |  January 17, 2023

Tumoral Calcinosis in Systemic Sclerosis Plain radiograph and computed tomography images depict calcinosis in the region of the right shoulder, left elbow and cervical spine of a 71-year-old woman with a 20-year history of systemic sclerosis. Manifestations include high-titer anti-Scl-70 antibody, diffuse skin involvement, Raynaud’s syndrome, acro-osteolysis, gastroesophageal reflux disease, interstitial lung disease and complete…

Lost and found

A Look Back at the First Use of Cortisone in Rheumatoid Arthritis

Ruth Jessen Hickman, MD  |  January 17, 2023

In 1949, the first description of patients with rheumatoid arthritis (RA) given cortisone sent shockwaves through the medical community, quickly capturing the public imagination as well. The paradigm-shifting report paved the way for the use of cortisone and related drugs in RA and many other medical conditions.1 The following is a discussion of some of…

  • « Previous Page
  • 1
  • …
  • 77
  • 78
  • 79
  • 80
  • 81
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences